Prognostic Factors and a Predictive Nomogram of Cancer-Specific Survival of Epithelial Ovarian Cancer Patients with Pelvic Exenteration Treatment
Open Access
- 17 August 2023
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2023, 1-12
Abstract
Objective. The aim of this study was to explore prognostic factors, develop and internally validate a prognostic nomogram model, and predict the cancer-specific survival (CCS) of epithelial ovarian cancer (EOC) patients with pelvic exenteration (PE) treatment. Methods. A total of 454 EOC patients from the Surveillance, Epidemiology, and End Results (SEER) database were collected according to the inclusion criteria and randomly divided into the training (n=317) and validation (n=137) cohorts. Prognostic factors of EOC patients with PE treatment were explored by univariate and multivariate stepwise Cox regression analyses. A predictive nomogram was constructed based on selected risk factors. The predictive power of the constructed nomogram was assessed by the time-dependent receiver operating characteristic (ROC) curve. KaplanMeier (KM) curve stratified by patients nomoscore was also plotted to assess the risk stratification of the established nomogram. In internal validation, the C index, calibration curve, and decision curve analysis (DCA) were employed to assess the discrimination, calibration, and clinical utility of the models, respectively. Results. In the training cohort, age, histological type, Federation of Gynecology and Obstetrics (FIGO) stage, number of examined lymph nodes, and number of positive lymph nodes were found to be independent prognostic factors of postoperative CSS. A practical nomogram model of EOC patients with PE treatment was constructed based on these selected risk factors. Time-dependent ROC curves and KM curves showed the superior predictive capability and excellent clinical stratification of the nomogram in both training and validation cohorts. In the internal validation, the C index, calibration plots, and DCA in the training and validation cohorts confirmed that the nomogram presents a high level of prediction accuracy and clinical applicability. Conclusion. Our nomogram exhibited satisfactory survival prediction and prognostic discrimination. It is a user-friendly tool with high clinical pragmatism for estimating prognosis and guiding the long-term management of EOC patients with PE treatment.Keywords
Funding Information
- Nanjing Medical University (PY2022032, SYH-3201160-0056, 82273199, BK20221417, ZDXK202239)
- Laboratory Medicine Research of Jiangsu Medical Association (PY2022032, SYH-3201160-0056, 82273199, BK20221417, ZDXK202239)
- National Natural Science Foundation of China (PY2022032, SYH-3201160-0056, 82273199, BK20221417, ZDXK202239)
- Natural Science Foundation of Jiangsu Province (PY2022032, SYH-3201160-0056, 82273199, BK20221417, ZDXK202239)
- Key Medical Subjects of Jiangsu Province (PY2022032, SYH-3201160-0056, 82273199, BK20221417, ZDXK202239)
This publication has 31 references indexed in Scilit:
- A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancerOncotarget, 2016
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumorsAnnals of Oncology, 2016
- Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian MetastasesInternational Journal of Gynecological Cancer, 2015
- Nomograms in oncology: more than meets the eyeThe Lancet Oncology, 2015
- Survival after pelvic exenteration for T4 rectal cancerBritish Journal of Surgery, 2014
- Survival After Curative Pelvic Exenteration for Primary or Recurrent Cervical CancerInternational Journal of Gynecological Cancer, 2014
- How To Build and Interpret a Nomogram for Cancer PrognosisJournal of Clinical Oncology, 2008
- Total pelvic exenteration: The Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003)Gynecologic Oncology, 2006
- Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLAGynecologic Oncology, 2005
- X-TileClinical Cancer Research, 2004